drugset / Trial / NCT03610048

A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)

NCT03610048

Phase 3 Terminated 175 enrolled Alkermes, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study will assess the long-term safety and tolerability of ALKS 5461 as an adjunctive treatment for refractory MDD.

Timeline

Start
2018-08-09
Primary completion
2020-05-01
Completion
2020-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified Subcutaneous
Subject Samidorphan Small molecule Subcutaneous